Premier Asset Management LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,550 shares of the biopharmaceutical company’s stock after selling 3,900 shares during the period. Premier Asset Management LLC’s holdings in Gilead Sciences were worth $612,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. Janus Henderson Group PLC raised its position in shares of Gilead Sciences by 1.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,781,907 shares of the biopharmaceutical company’s stock valued at $144,366,000 after acquiring an additional 30,713 shares during the period. Vident Investment Advisory LLC raised its position in shares of Gilead Sciences by 33.2% in the 3rd quarter. Vident Investment Advisory LLC now owns 48,967 shares of the biopharmaceutical company’s stock valued at $3,967,000 after acquiring an additional 12,202 shares during the period. Chevy Chase Trust Holdings Inc. raised its position in shares of Gilead Sciences by 1.2% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,145,434 shares of the biopharmaceutical company’s stock valued at $92,806,000 after acquiring an additional 13,451 shares during the period. Mastrapasqua Asset Management Inc. raised its position in shares of Gilead Sciences by 1.0% in the 3rd quarter. Mastrapasqua Asset Management Inc. now owns 101,651 shares of the biopharmaceutical company’s stock valued at $8,235,000 after acquiring an additional 979 shares during the period. Finally, Sectoral Asset Management Inc acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $19,032,000. Institutional investors own 75.84% of the company’s stock.

A number of analysts recently weighed in on the stock. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price target on the stock in a research report on Monday. Maxim Group set a $94.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday. Leerink Swann increased their price target on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research report on Thursday, October 19th. Mizuho increased their price target on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Finally, Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $85.58.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $80.38 on Wednesday. The firm has a market cap of $102,372.30, a P/E ratio of 9.15, a PEG ratio of -1.73 and a beta of 1.22. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $89.54. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s quarterly revenue was down 18.7% on a year-over-year basis. During the same period last year, the business earned $2.70 EPS. equities research analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 2.84%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is presently 23.69%.

In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider John F. Milligan sold 220,000 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. In the last three months, insiders sold 578,333 shares of company stock valued at $44,100,508. 1.30% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “Premier Asset Management LLC Cuts Holdings in Gilead Sciences, Inc. (GILD)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/premier-asset-management-llc-cuts-holdings-in-gilead-sciences-inc-gild/1850044.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.